Predictive Oncology partners with Cvergenx to create new genomics-based AI radiation therapy | News Direct

Predictive Oncology partners with Cvergenx to create new genomics-based AI radiation therapy

News release by Predictive Oncology Inc.

facebook icon linkedin icon twitter icon pinterest icon email icon New York | March 01, 2023 07:14 AM Eastern Standard Time

Predictive Oncology CEO Raymond Vennare and Cvergenx CEO Javier Torres-Roca join Natalie Stoberman to share news of their new partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence (AI).

Vennare said the objective of this collaboration will be to leverage Predictive Oncology’s drug discovery, AI and machine learning capabilities with the Cvergenx precision genomics radiation therapy platform.

 

 

Contact Details

 

Proactive US

 

+1 347-449-0879

 

na-editorial@proactiveinvestors.com

Tags

proactiveinvestorspredictiveoncologycvergenxNASDAQPOAIradiationgenomicsartificialintelligencepartnershipdrugdiscoveryinvestinvestinginvestmentinvestorstockmarketstocksstockstockmarketnews